Cilostazol for Intermittent Claudication
Recommended Initiation Dose
Start cilostazol at 100 mg orally twice daily, taken at least 30 minutes before or at least 2 hours after breakfast and dinner to optimize absorption. 1, 2, 3
- This standard dose improves maximal walking distance by 40–60% compared with placebo after 12–24 weeks of therapy. 1
- The 100 mg twice-daily regimen is significantly more effective than the 50 mg twice-daily dose in head-to-head comparisons. 1
- Reduce the dose to 50 mg twice daily only if the patient is taking concomitant CYP3A4 inhibitors (e.g., erythromycin, diltiazem) or CYP2C19 inhibitors (e.g., omeprazole). 1, 4
Absolute Contraindications
Cilostazol is absolutely contraindicated in any patient with heart failure of any severity, regardless of ejection fraction or NYHA class. 5, 1, 2
- The FDA mandates a black-box warning against use in heart failure because other phosphodiesterase-III inhibitors (milrinone, vesnarinone) have demonstrated increased mortality in heart-failure populations. 1, 2
- Also contraindicated in patients with active pathologic bleeding (e.g., bleeding peptic ulcer, intracranial hemorrhage) or hemostatic disorders. 2
- Contraindicated in patients with known hypersensitivity to cilostazol or any component. 2
- European regulators contraindicate cilostazol entirely when CYP3A4 or CYP2C19 inhibitors are co-administered, whereas U.S. guidance permits dose reduction to 50 mg twice daily. 1, 4
Monitoring Protocol
Assess patient tolerance at 2–4 weeks after initiation to identify intolerable adverse effects. 5, 1
- Common adverse effects include headache (occurs 2.8-fold more often than placebo), diarrhea, abnormal stools, palpitations, and dizziness. 5, 6, 4, 7
- Approximately 20% of patients discontinue cilostazol within 3 months due to these adverse effects. 5, 6
- Evaluate clinical benefit at 3–6 months to determine whether long-term therapy is warranted. 5, 1
- If headache or gastrointestinal symptoms persist or become intolerable, consider dose reduction to 50 mg twice daily (though this reduces efficacy) or discontinue the medication. 6
No dedicated blood-pressure monitoring protocol is required. 6
- Cilostazol does not cause clinically significant hypotension; dizziness is attributed to vasodilatory and phosphodiesterase-III inhibitory actions rather than blood-pressure reduction. 6
- Standard cardiovascular risk-factor surveillance is sufficient. 6
- The CASTLE trial (1,435 participants, up to 36 months) demonstrated no increase in all-cause mortality, cardiovascular mortality, serious bleeding, or hypotension-related events with cilostazol versus placebo. 6
Important Clinical Caveats
Cilostazol improves claudication symptoms but does NOT reduce cardiovascular ischemic events (myocardial infarction, stroke, or cardiovascular death). 5, 6
- The sole FDA-approved indication is symptom relief for intermittent claudication—it provides no cardiovascular protection. 1, 2
- Long-term safety data from trials enrolling >2,000 patients showed cardiovascular death rates of 0.6% with cilostazol versus 0.5% with placebo, indicating no excess mortality risk in patients without heart failure. 1
Screen for subclinical heart failure before prescribing cilostazol. 8
- Evaluate for any history or symptoms of heart failure, including dyspnea, orthopnea, peripheral edema, or reduced exercise tolerance. 8
- Assessment of left ventricular function is prudent given the absolute contraindication in heart failure of any severity. 8
Cilostazol may be useful to reduce restenosis after endovascular therapy for femoropopliteal disease. 5
- In a blinded RCT, cilostazol improved primary patency at 3 years after bare-metal femoropopliteal stent treatment. 5
- A meta-analysis of 3 RCTs and 5 observational studies (3,846 patients) showed cilostazol improved primary patency, target lesion revascularization, and major adverse limb events after femoropopliteal endovascular therapy. 5